Join        Login             Stock Quote

Biogen Idec (BIIB) Initiated as 'Buy' by Brean Capital, PT $184

 November 21, 2012 10:19 AM

(By Balachander) Biogen Idec Inc. (NASDAQ: BIIB) shares were initiated with a "buy" rating and price target of $184 by Brean Capital LLC.

Over the near term, BIIB's share price is likely to be driven by how investors contemplate the launch of the oral MS drug BG-12, market opportunity for hemophilia treatments, and upcoming data for Dexpramipexole in ALS, the brokerage said.

In 2011, Brean Capital said, two pivotal phase III trials for BG-12 in MS created an inflection point that took the market value of the drug from hundreds of millions to billions. "With BG-12, BIIB becomes the leading MS company on the globe," the brokerage wrote.

[Related -Biogen Idec Inc (BIIB): Top Reasons To Own Biogen Idec]

"Together with Tysabri, Avonex and its Lingo development program, BIIB's broad MS portfolio addresses the needs of any MS patient, creating a daunting challenge for any competitor to counter detail," Brean Capital said.

Brean Capital expects BIIB to enter 2013 preparing regulatory filings in hemophilia and ALS that each represent potential $1b+market opportunities not yet included in its profit forecasts.

"We believe 2013 will be a transformational year for BIIB," the brokerage said. "We believe the shares will continue to outperform over the next 12 months on the stability of BIIB's MS base business while the late stage pipeline sets the stage for accelerated top- and bottom-line growth beyond 2013."

The stock, which has been trading in the 52-week range of $107.41 to $157.18, added 0.72 percent to trade at $149.22 on Wednesday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.